- Science & technologyScience & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
- Who we areWho we are
We are a biotechnology company committed to help address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
- Insights
Novavax to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Novavax today announced that it will participate in the 41st Annual J.P. Morgan Healthcare Conference.
Conference Details: Presentation and Q&A |
| ||
Date: | Monday, January 9, 2023 | ||
Time: | 5:15 – 5:55 p.m. Pacific Standard Time (PST) | ||
Location: | Westin St. Francis Hotel in San Francisco, California | ||
J.P. Morgan moderator: | Eric Joseph, Ph.D., Equity Research Analyst – Biotechnology | ||
Novavax participant: | Stanley C. Erck, President and Chief Executive Officer | ||
| |||
Conference |
| ||
Event: | Investor meetings | ||
Date: | Monday, January 9, 2023 | ||
Recordings
A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company’s website at ir.novavax.com for 30 days.
